News
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)